Plain-English translation of NCT05834855 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether works just as well as ocrelizumab—two similar medications that calm down the immune system in relapsing multiple sclerosis. Both medications are already used to treat MS, but this study will confirm whether the medication being tested is as effective and safe as the standard treatment, which could make MS care more affordable.
Ocrelizumab is an effective MS treatment, but it's expensive. Early research suggests that —a similar and much cheaper medication—works just as well. If this trial proves that, patients and healthcare systems could save significant money without losing any treatment benefit.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the standard medication or the one being tested, given as infusions (IV injections) every two weeks initially. You'll visit the hospital or clinic multiple times over 30 months for MRI brain scans, blood tests, neurological exams, and questionnaires about your symptoms and quality of life. The study is 'double-blind,' meaning neither you nor your doctors will know which medication you're receiving—only the research team will know.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Netherlands